Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Cidara Therapeutics, Inc. (NASDAQ: CDTX).

Full DD Report for CDTX

You must become a subscriber to view this report.


Recent News from (NASDAQ: CDTX)

Cidara Therapeutics misses by $0.15
Cidara Therapeutics (NASDAQ: CDTX ): Q1 EPS of -$0.80 misses by $0.15 . More news on: Cidara Therapeutics, Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: May, 10 2018 17:02
Cidara Provides Corporate Update and Reports First Quarter 2018 Financial Results
SAN DIEGO, May 10, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months ended March 31, 2018 and provided an update on its corporate ac...
Source: GlobeNewswire
Date: May, 10 2018 16:05
Antimicrobials Working Group Highlights Member Company Participation at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
WASHINGTON , April 20, 2018 /PRNewswire/ -- The Antimicrobials Working Group (AWG) today announced that thirteen of its member companies will present data from their clinical and research programs at the annual meeting of the European Congress of Clinical Microbiology and Infectious ...
Source: PR Newswire
Date: April, 20 2018 10:17
Key events next week - healthcare
Noteworthy events during the week of April 15 - 21 for healthcare investors. More news on: Bristol-Myers Squibb Company, Biondvax Pharmaceuticals, Rigel Pharmaceuticals, Inc., Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: April, 13 2018 09:56
Cidara Therapeutics to Present Rezafungin Data at the European Congress of Clinical Microbiology and Infectious Diseases 2018 Meeting
Company secures four oral presentations, including three that will highlight new data demonstrating activity of rezafungin against Candida auris and azole-resistant Aspergillus Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives includi...
Source: Business Wire
Date: April, 04 2018 08:00
Cidara Therapeutics Provides Clinical Data Updates for its Lead Antifungal Rezafungin
Additional data and analyses from  STRIVE Phase 2 clinical trial confirm positive efficacy results in both rezafungin arms Definitive Phase 1 QT clinical trial showed no cardiac abnormalities SAN DIEGO, March 21, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq...
Source: GlobeNewswire
Date: March, 21 2018 08:00
Blog Exposure - Cidara Therapeutics Released Positive Top-line Results from Phase-2 STRIVE Trial Assessing its Lead Antifungal Rezafungin
Stock Monitor: BioTime Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 21, 2018 / Active-Investors.com has just released a free research report on Cidara Therapeutics, Inc. (NASDAQ: CDTX ). If you want access to this report all you need to do is sign up now by clicking the fo...
Source: ACCESSWIRE IA
Date: March, 21 2018 07:40
Cidara: Can The Market Be That Stupid?
Sometimes it happens in biotech: Following positive trial results a stock sells off. However, the contradiction might be only apparent, if the market had already priced in much of the potential positives before the publication and the effective results then "don't beat estimates". Hence, it's ...
Source: SeekingAlpha
Date: March, 21 2018 04:25
U.S. Biotech/Pharma Sector Daily Observations Letter: March 19, 2018
The overall market continued its sideways consolidation pattern with today being a down day (advancers: decliners= 21%: 71%). Ongoing political turmoil (repeated staff firings by Trump, Mueller investigation) and a big down for Facebook (NASDAQ: FB ) contributed to the decline today. Fed ...
Source: SeekingAlpha
Date: March, 20 2018 11:35
Cidara Should Be On Your Radar After Positive Phase 2 Despite The Drop In Share Price
Cidara Therapeutics ( CDTX ) announced recently that its drug candidate rezafungin acetate met the primary endpoint for a phase 2 study treating patients with candidemia and/or invasive candidiasis. The stock traded lower by 20% and was sold off. However, the data in question is highly...
Source: SeekingAlpha
Date: March, 20 2018 09:52

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-255.755.956.055.50416,663
2018-05-245.255.4255.4955.15206,388
2018-05-235.005.205.454.95311,730
2018-05-224.604.905.154.30414,489
2018-05-214.654.554.7254.30225,983

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-05-2556,787140,13540.5231Short
2018-05-2422,12239,89355.4533Short
2018-05-2322,75380,96328.1030Cover
2018-05-2234,70385,60740.5376Short
2018-05-2123,51267,42534.8713Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CDTX.


About Cidara Therapeutics, Inc. (NASDAQ: CDTX)

Logo for Cidara Therapeutics, Inc. (NASDAQ: CDTX)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $85,161,719 - 05/11/2018
  • Issue and Outstanding: 20,771,151 - 02/20/2018

 


Recent Filings from (NASDAQ: CDTX)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 10 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 10 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 27 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 27 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 26 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 21 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 19 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 19 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 27 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: February, 27 2018

 

 


Daily Technical Chart for (NASDAQ: CDTX)

Daily Technical Chart for (NASDAQ: CDTX)


Stay tuned for daily updates and more on (NASDAQ: CDTX)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: CDTX)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

The Subway Trader
@TheSubwayTrader

 

 


Disclaimer: The Subway Trader publishes reports providing information on selected companies. The Subway Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. The Subway Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CDTX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. The Subway Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. The Subway Trader does not own any shares of CDTX and does not buy, sell, or trade any shares of CDTX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by The Subway Trader. All rights reserved. Our Full Disclaimer: http://thesubwaytrader.com/disclaimer/